Profile data is unavailable for this security.
About the company
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
- Revenue in CHF (TTM)87.41m
- Net income in CHF-4.66m
- Incorporated1995
- Employees122.00
- LocationKuros Biosciences AGWagistrasse 25SCHLIEREN 8952SwitzerlandCHE
- Phone+41 447334747
- Fax+41 447334740
- Websitehttps://kurosbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Philogen SpA | 71.80m | 41.88m | 576.09m | 193.00 | 18.99 | 6.91 | 12.64 | 8.02 | 1.14 | 1.14 | 1.96 | 3.13 | 0.5961 | 5.65 | 21.87 | 430,158.50 | 34.77 | 0.7964 | 40.11 | 0.8907 | 74.04 | 58.86 | 58.33 | 3.70 | 5.52 | -- | 0.0837 | -- | 219.91 | 42.46 | 835.14 | 100.38 | 10.46 | -- |
| Valneva SE | 164.09m | -93.18m | 682.93m | 700.00 | -- | 4.96 | -- | 4.16 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Basilea Pharmaceutica AG Allschwil | 236.21m | 72.66m | 741.94m | 180.00 | 10.64 | 6.63 | 9.95 | 3.14 | 5.23 | 5.23 | 17.03 | 8.40 | 1.08 | 1.66 | 10.57 | 1,440,305.00 | 33.21 | 7.08 | 39.78 | 11.18 | 81.04 | 82.50 | 30.76 | 9.96 | 5.67 | 31.61 | 0.4428 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
| Gubra A/S | 321.98m | 213.23m | 760.13m | 275.00 | -- | 5.12 | -- | 2.36 | -1.03 | -1.03 | 161.54 | 74.35 | 1.50 | -- | 68.31 | 11,174,780.00 | 99.21 | -- | 190.28 | -- | 3.52 | -- | 66.22 | -- | -- | -- | 0.0709 | -- | 29.63 | -- | 18.03 | -- | -- | -- |
| Nanobiotix SA | -12.81m | -47.10m | 940.28m | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Evotec SE | 689.81m | -145.00m | 977.62m | 4.79k | -- | 1.34 | -- | 1.42 | -0.8955 | -0.8955 | 4.26 | 4.50 | 0.4019 | 20.15 | 5.17 | 156,687.00 | -8.45 | -2.40 | -10.41 | -2.87 | 10.82 | 21.49 | -21.02 | -6.78 | 2.03 | -2.54 | 0.3772 | -- | 1.99 | 12.29 | -133.67 | -- | 32.89 | -- |
| Kuros Biosciences AG | 87.41m | -4.66m | 981.81m | 122.00 | -- | 16.09 | -- | 11.23 | -0.122 | -0.1352 | 2.26 | 1.56 | 1.16 | 1.75 | 7.11 | 716,481.60 | -6.18 | -10.85 | -7.79 | -12.28 | 83.57 | 84.11 | -5.33 | -31.80 | 1.74 | -0.4702 | 0.0655 | -- | 129.67 | 101.59 | 62.67 | -- | 60.45 | -- |
| Idorsia Ltd | 232.51m | -117.94m | 984.57m | 938.00 | -- | -- | -- | 4.23 | -0.6593 | -0.6593 | 1.06 | -4.88 | 0.4807 | 0.3793 | 796.27 | -- | -24.38 | -48.63 | -53.54 | -61.12 | 86.49 | -- | -50.72 | -526.39 | 0.8345 | -6.02 | 31.03 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Inventiva SA | 12.41m | -283.71m | 993.98m | 84.00 | -- | -- | -- | 80.07 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Oxford BioMedica plc | 158.60m | -38.88m | 1.01bn | 900.00 | -- | 25.91 | -- | 6.39 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
Data as of Feb 16 2026. Currency figures normalised to Kuros Biosciences AG's reporting currency: Swiss Franc CHF
15.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 23 Oct 2025 | 1.16m | 2.97% |
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 955.89k | 2.44% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 28 Nov 2025 | 744.55k | 1.90% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 614.04k | 1.57% |
| Deka Investment GmbHas of 30 Sep 2025 | 588.80k | 1.50% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2025 | 586.88k | 1.50% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 435.58k | 1.11% |
| Janus Henderson Investors UK Ltd.as of 31 Dec 2025 | 426.62k | 1.09% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 366.57k | 0.94% |
| Banque Cantonale Vaudoise (Investment Management)as of 30 Sep 2025 | 181.23k | 0.46% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
